Prostate News Archive
15-Jul-2008
Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate ... (Business Wire via Yahoo! Finance)
THOUSAND OAKS, Calif.----Amgen today announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer. Drug prevents bone loss in prostate cancer: Amgen (Reuters via Yahoo! News)
In a study, Amgen Inc's experimental drug denosumab reduced the risk of osteoporosis and fracture in men being treated with prostate cancer medicines that can cause bone loss, the company said on Monday. Drug prevents bone loss in prostate cancer: Amgen (Reuters via Yahoo! News)
Amgen Inc on Monday said that a trial of its experimental drug denosumab showed that it can prevent osteoporosis in men being treated with prostate cancer drugs that can cause bone loss. Unite 2 fight: Race against prostate cancer run/walk (The Indianapolis Star)
Although Saturday's thunderstorms prompted the cancellation of the run, for which 3,500 people had registered, the event promoting prostate cancer awareness and remembering the legacy of the Rev. Charles Williams was moved into Indiana War Memorial auditorium. There, speakers including Sen. Richard Lugar, R-Ind., and Mayor Greg Ballard addressed survivors, their families and event participants.
Back to Prostate News Archive
